Evogene Reports Second Quarter and First Half 2026 Financial Results
Evogene reduced its second-quarter net loss to $1.8 million from $4.7 million a year ago, driven by a strategic transformation that cut the workforce from 117 to 38 employees and lowered annual cash burn guidance to $8.5–$9.5 million. The company raised $11.1 million since 2025 and holds $9.3 million in cash, while expanding its ChemPass AI platform to 110 billion molecules and securing six active drug collaborations.
Key figures
- Revenue
- 0.7 million
- Guidance
- Full-year 2026 cash usage expected to be $8.5 million to $9.5 million
- Revenue Yoy
- -75.9%
- Net loss q2
- 1.8 million
- Cash position
- 9.3 million
- Active collaborations
- 6
- Annual cash burn guidance
- 8.5-9.5 million
- Virtual chemical space molecules
- 110 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.